Prospective randomized controlled study of Zengneng Jiedu Formula for asymptomatic and mild COVID-19 patients  

作　　者：Ping-Fan Shi Song-Yuan Yu Fei Wang Yu-Ting Zhang Shuang-Er Ma Jian-Ping Ma Li-Hong Fan Ming Li 

机构地区：[1]Department of Infectious Diseases,Shanghai Tenth People's Hospital,No.301,Middle Yanchang Road,Jing'an District,Shanghai 200072,China [2]Department of Medical Ultrasonics,Shanghai Tenth People's Hospital,No.301,Middle Yanchang Road,Jing'an District,Shanghai 200072,China [3]Department of Traditional Chinese Medicine,Shanghai Tenth People's Hospital,No.301,Middle Yanchang Road,Jing'an District,Shanghai 200072,China [4]Department of Traditional Chinese Medicine,Changji People's Hospital,Yan'an North Road,Changji City,Xinjiang 831100,China [5]Department of Respiratory Medicine,Shanghai Sixth People's Hospital,No.600,Yishan Road,Xuhui District,Shanghai 200233,China.

出　　处：《Natural Therapy Advances》2025年第1期70-75,共6页

基　　金：supported by the Construction Fund of Shanghai Innovative Flagship Hospital of Integrated Traditional Chinese and Western Medicine(ZY(2021-2023)-0205-05);the Special TCM Emergency Response Project for Novel Coronavirus Infection of the State Administration of Traditional Chinese Medicine(2023ZYLCYJ02-6).

摘　　要：Background:To investigate the clinical value of Zengneng Jiedu Formula in treating asymptomatic and mild COVID-19 patients.Methods:Asymptomatic and mild COVID-19 patients admitted to the Changji Stadium Fangcang Hospital were randomly divided into treatment and control groups in a 1:1 ratio.The treatment group received Zengneng Jiedu Formula in addition to the standard treatment protocol outlined in the Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia.The control group received the standard treatment protocol alone.The hospitalization duration and time to viral clearance were compared between the two groups.The study adhered to CONSORT guidelines and was registered at the Chinese Clinical Trial Registry(ChiCTR2200060589).Results:A total of 246 patients completed the entire treatment and assessment.Data analysis after treatment showed that Zengneng Jiedu Formula significantly reduced the hospitalization duration for asymptomatic and mild COVID-19 patients(7.06 days vs.8.01 days,P<0.001)and shortened the overall time to viral clearance(8.58 days vs.10.12 days,P<0.001).The incidence of adverse events was similar between the two groups.Conclusion:Zengneng Jiedu Formula can effectively shorten the hospitalization duration and time to viral clearance for asymptomatic and mild COVID-19 patients,providing a safe and effective treatment option that warrants clinical application and further study.

关 键 词：COVID-19 infection Zengneng Jiedu Formula traditional Chinese medicine clinical study time to viral clearance 

分 类 号：R259[医药卫生—中西医结合]